Two cancer genetics researchers at the Icahn School of Medicine at Mount Sinai have received a grant from the Liddy Shriver Sarcoma Initiative to support promising research on a genetic mutation in hereditary bone cancer called osteosarcoma. New York, NY (PRWEB) February 01, 2013 John Martignetti, MD, PhD and Olga Camacho-Vanegas, PhD discovered that mutations in newly described and previously unknown forms of the methylthioadenosine phosphorylase (MTAP) gene result in hereditary osteosarcoma and Malignant Fibrous Histiocytoma (MFH)two rare bone cancers that usually affect children, adolescents and young adults. Osteosarcoma and MFH are treated with a combination of aggressive therapies, but a significant number of patients deal with disease relapse and progression. With support from the Liddy Shriver Sarcoma Initiative Grant, the scientists hope to find out why MTAP mutations result in cancer and how common they are, then evaluate MTAP as a therapeutic target. Our goal is to evaluate how common MTAP mutations are in bone cancer and determine their therapeutic relevance, said Dr. Martignetti, who is Associate Professor of Genetics and Genomics Sciences; Oncological Sciences; and Pediatrics at the Graduate School of Biomedical Sciences at Mount Sinai. We are honored to be recognized by the Liddy Shriver Sarcoma Initiative, … Continue reading →

Cabo's Stemlogix Stem Cell Treatment "Cabo was so weak in her hind quarters, she couldn't stand in one place without her back legs sliding. Also, fell asleep everywhere and just didn't care much about anything. Totally the opposite of now!" -Debi (Cabo's Mom) Below is a video of Cabo taken by Debi, Cabo's mom, a month and a half after stem cell therapy! Yea Cabo! By: StemLogixLLC … Continue reading →

Buyer's 12 Month Recheck - Gait Analysis After being diagnosed with medial shoulder instability in April 2009, Buyer was treated with stem cell therapy at VOSM. This gait analysis is from May 2010, more than a year after treatment. By: VetSportsMedicine … Continue reading →

MSI Scope - Post-Radiofrequency Treatment Buyer Merrill came to VOSM in 2009 with moderate medial shoulder instability. He was treated with radiofrequency treatment and stem cell therapy. This is his post-surgical scope. By: VetSportsMedicine … Continue reading →

MSI 2nd Look - Post Stem Cell Therapy Buyer came to VOSM in 2009 with medial shoulder instability. He had stem cell injections in the spring and came back in the summer for a second look scope. The shoulder tissue had repaired and regenerated. By: VetSportsMedicine … Continue reading →

RedChip Money Report with Dave Gentry: Episode 12 This week's episode of "The RedChip Money Report" features interviews with Seth Grae, CEO of Lightbridge Corp. (NASDAQ: LTBR), a US nuclear energy company; Dr. Robin Smith, Chairman and CEO of NeoStem, Inc. (NYSE MKT: NBS), a stem cell therapy company; and Robert Miller, CEO of Abakan, Inc. (OTCQB: ABKI), a developer and manufacturer of advanced nanocomposite materials. "The RedChip Money Report" trade; delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The show is hosted by Dave Gentry, a leading authority on small-cap stocks and president of RedChip, an international small-cap research firm and an Inc. 5000 company. Mr. Gentry has made multiple guest appearances on both CNBC and Fox Business News and has been a consultant to hundreds of public companies. "The RedChip Money Report" trade; airs Saturdays at 2:30 pm on Fox Business News, a premium business network reaching more than 65 million homes nationwide. The weekly program also airs on My Family TV and TUFF TV. By: RedChip Money Report Gentry … Continue reading →